Jefferies initiated coverage of Emerson (EMR) with a Buy rating and $160 price target The firm sees a recovery in manufacturing sentiment, bolstered by the potential for lower interest rates, reduced corporate taxes, and deregulation. In the context of this view, the analyst notes Emerson is nearing the completion of its portfolio transformation and expects continued strength in process and a discrete and T&M recovery to drive growth in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR:
- Emerson price target raised to $158 from $140 at KeyBanc
- Emerson price target raised to $135 from $116 at Barclays
- Emerson price target raised to $155 from $130 at Loop Capital
- Merck elects Surendralal Karsanbhai to board of directors
- Aspen Technology board forms special committee to consider Emerson proposal